Table 2. Baseline characteristics at antiretroviral therapy initiation (N = 4868).
| Characteristic | Frequency n (%) | ||
|---|---|---|---|
| Died | Alive | Total | |
| Sex | |||
| Female | 300 (59.3) | 2723 (62.4) | 3023 (62.1) |
| Male | 206 (40.7) | 1639 (37.6) | 1845 (37.9) |
| Age, median (IQR) | 35 (17–47) | 33 (16–40) | 33 (16–41) |
| Age Groups | |||
| Paediatrics (0–12 years) | 79 (15.6) | 864 (19.8) | 943 (19.4) |
| Adolescents (13–19 years) | 68 (13.4) | 366 (8.4) | 434 (8.9) |
| Adults (>19 years) | 359 (70.9) | 3132 (71.85) | 3491 (71.7) |
| CD4 categories (cells/mm3) | |||
| > 500 | 20 (4.0) | 438 (10.0) | 458 (9.4) |
| 350–500 | 31 (6.1) | 451 (10.3) | 482 (9.9) |
| 100–349 | 179 (35.4) | 2365 (54.2) | 2544 (52.3) |
| < 100 | 272 (53.8) | 1069 (24.5) | 1341 (27.5) |
| Clinical WHO Stage* | |||
| 1 | 27 (5.3) | 778 (17.8) | 805 (16.5) |
| 2 | 50 (9.9) | 737 (16.9) | 787 (16.2) |
| 3 | 173 (34.2) | 988 (22.7) | 1161 (23.8) |
| 4 | 102 (20.2) | 326 (7.5) | 428 (8.8) |
| Pre-existing malignancy | 16 (3.2) | 27 (0.6) | 43 (0.9) |
| Year of ART initiation | |||
| 2004–2007 | 238 (47.0) | 1115 (25.6) | 1353 (27.8) |
| 2008–2011 | 175 (34.6) | 1666 (38.2) | 1841 (37.8) |
| 2012–2017 | 93 (18.4) | 1581 (36.2) | 1674 (34.4) |
*1687 Patients did not have a recorded WHO stage